Copyright Reports & Markets. All rights reserved.

Global Herceptin Biosimilar Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Herceptin Biosimilar
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Herceptin Biosimilar Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Breast Cancer
    • 1.3.3 Colorectal Cancer
    • 1.3.4 Leukemia
    • 1.3.5 Lymphoma
    • 1.3.6 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Herceptin Biosimilar Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital & Clinics
    • 1.4.3 Oncology Centers
    • 1.4.4 Other
  • 1.5 Global Herceptin Biosimilar Market Size & Forecast
    • 1.5.1 Global Herceptin Biosimilar Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Herceptin Biosimilar Sales Quantity (2019-2030)
    • 1.5.3 Global Herceptin Biosimilar Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Amgen
    • 2.1.1 Amgen Details
    • 2.1.2 Amgen Major Business
    • 2.1.3 Amgen Herceptin Biosimilar Product and Services
    • 2.1.4 Amgen Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Amgen Recent Developments/Updates
  • 2.2 AryoGen Biopharma
    • 2.2.1 AryoGen Biopharma Details
    • 2.2.2 AryoGen Biopharma Major Business
    • 2.2.3 AryoGen Biopharma Herceptin Biosimilar Product and Services
    • 2.2.4 AryoGen Biopharma Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 AryoGen Biopharma Recent Developments/Updates
  • 2.3 Biocon
    • 2.3.1 Biocon Details
    • 2.3.2 Biocon Major Business
    • 2.3.3 Biocon Herceptin Biosimilar Product and Services
    • 2.3.4 Biocon Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Biocon Recent Developments/Updates
  • 2.4 Celltrion
    • 2.4.1 Celltrion Details
    • 2.4.2 Celltrion Major Business
    • 2.4.3 Celltrion Herceptin Biosimilar Product and Services
    • 2.4.4 Celltrion Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Celltrion Recent Developments/Updates
  • 2.5 Gedeon Richter
    • 2.5.1 Gedeon Richter Details
    • 2.5.2 Gedeon Richter Major Business
    • 2.5.3 Gedeon Richter Herceptin Biosimilar Product and Services
    • 2.5.4 Gedeon Richter Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Gedeon Richter Recent Developments/Updates
  • 2.6 Genor Biopharma
    • 2.6.1 Genor Biopharma Details
    • 2.6.2 Genor Biopharma Major Business
    • 2.6.3 Genor Biopharma Herceptin Biosimilar Product and Services
    • 2.6.4 Genor Biopharma Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Genor Biopharma Recent Developments/Updates
  • 2.7 Mabion
    • 2.7.1 Mabion Details
    • 2.7.2 Mabion Major Business
    • 2.7.3 Mabion Herceptin Biosimilar Product and Services
    • 2.7.4 Mabion Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Mabion Recent Developments/Updates
  • 2.8 Mylan
    • 2.8.1 Mylan Details
    • 2.8.2 Mylan Major Business
    • 2.8.3 Mylan Herceptin Biosimilar Product and Services
    • 2.8.4 Mylan Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Mylan Recent Developments/Updates
  • 2.9 Roche
    • 2.9.1 Roche Details
    • 2.9.2 Roche Major Business
    • 2.9.3 Roche Herceptin Biosimilar Product and Services
    • 2.9.4 Roche Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Roche Recent Developments/Updates
  • 2.10 The Instituto Vital Brazil
    • 2.10.1 The Instituto Vital Brazil Details
    • 2.10.2 The Instituto Vital Brazil Major Business
    • 2.10.3 The Instituto Vital Brazil Herceptin Biosimilar Product and Services
    • 2.10.4 The Instituto Vital Brazil Herceptin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 The Instituto Vital Brazil Recent Developments/Updates

3 Competitive Environment: Herceptin Biosimilar by Manufacturer

  • 3.1 Global Herceptin Biosimilar Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Herceptin Biosimilar Revenue by Manufacturer (2019-2024)
  • 3.3 Global Herceptin Biosimilar Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Herceptin Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Herceptin Biosimilar Manufacturer Market Share in 2023
    • 3.4.2 Top 6 Herceptin Biosimilar Manufacturer Market Share in 2023
  • 3.5 Herceptin Biosimilar Market: Overall Company Footprint Analysis
    • 3.5.1 Herceptin Biosimilar Market: Region Footprint
    • 3.5.2 Herceptin Biosimilar Market: Company Product Type Footprint
    • 3.5.3 Herceptin Biosimilar Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Herceptin Biosimilar Market Size by Region
    • 4.1.1 Global Herceptin Biosimilar Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Herceptin Biosimilar Consumption Value by Region (2019-2030)
    • 4.1.3 Global Herceptin Biosimilar Average Price by Region (2019-2030)
  • 4.2 North America Herceptin Biosimilar Consumption Value (2019-2030)
  • 4.3 Europe Herceptin Biosimilar Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Herceptin Biosimilar Consumption Value (2019-2030)
  • 4.5 South America Herceptin Biosimilar Consumption Value (2019-2030)
  • 4.6 Middle East and Africa Herceptin Biosimilar Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 5.2 Global Herceptin Biosimilar Consumption Value by Type (2019-2030)
  • 5.3 Global Herceptin Biosimilar Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 6.2 Global Herceptin Biosimilar Consumption Value by Application (2019-2030)
  • 6.3 Global Herceptin Biosimilar Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 7.2 North America Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 7.3 North America Herceptin Biosimilar Market Size by Country
    • 7.3.1 North America Herceptin Biosimilar Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Herceptin Biosimilar Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 8.2 Europe Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 8.3 Europe Herceptin Biosimilar Market Size by Country
    • 8.3.1 Europe Herceptin Biosimilar Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Herceptin Biosimilar Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Herceptin Biosimilar Market Size by Region
    • 9.3.1 Asia-Pacific Herceptin Biosimilar Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Herceptin Biosimilar Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 10.2 South America Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 10.3 South America Herceptin Biosimilar Market Size by Country
    • 10.3.1 South America Herceptin Biosimilar Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Herceptin Biosimilar Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Herceptin Biosimilar Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Herceptin Biosimilar Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Herceptin Biosimilar Market Size by Country
    • 11.3.1 Middle East & Africa Herceptin Biosimilar Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Herceptin Biosimilar Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Herceptin Biosimilar Market Drivers
  • 12.2 Herceptin Biosimilar Market Restraints
  • 12.3 Herceptin Biosimilar Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Herceptin Biosimilar and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Herceptin Biosimilar
  • 13.3 Herceptin Biosimilar Production Process
  • 13.4 Herceptin Biosimilar Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Herceptin Biosimilar Typical Distributors
  • 14.3 Herceptin Biosimilar Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Herceptin Biosimilar market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
    Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    The Global Info Research report includes an overview of the development of the Herceptin Biosimilar industry chain, the market status of Hospital & Clinics (Breast Cancer, Colorectal Cancer), Oncology Centers (Breast Cancer, Colorectal Cancer), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Herceptin Biosimilar.
    Regionally, the report analyzes the Herceptin Biosimilar markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Herceptin Biosimilar market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Herceptin Biosimilar market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Herceptin Biosimilar industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Breast Cancer, Colorectal Cancer).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Herceptin Biosimilar market.
    Regional Analysis: The report involves examining the Herceptin Biosimilar market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Herceptin Biosimilar market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Herceptin Biosimilar:
    Company Analysis: Report covers individual Herceptin Biosimilar manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Herceptin Biosimilar This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital & Clinics, Oncology Centers).
    Technology Analysis: Report covers specific technologies relevant to Herceptin Biosimilar. It assesses the current state, advancements, and potential future developments in Herceptin Biosimilar areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Herceptin Biosimilar market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Herceptin Biosimilar market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Breast Cancer
    Colorectal Cancer
    Leukemia
    Lymphoma
    Other
    Market segment by Application
    Hospital & Clinics
    Oncology Centers
    Other
    Major players covered
    Amgen
    AryoGen Biopharma
    Biocon
    Celltrion
    Gedeon Richter
    Genor Biopharma
    Mabion
    Mylan
    Roche
    The Instituto Vital Brazil
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Herceptin Biosimilar product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Herceptin Biosimilar, with price, sales, revenue and global market share of Herceptin Biosimilar from 2019 to 2024.
    Chapter 3, the Herceptin Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Herceptin Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Herceptin Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Herceptin Biosimilar.
    Chapter 14 and 15, to describe Herceptin Biosimilar sales channel, distributors, customers, research findings and conclusion.

    Buy now